Evidence map›Paper›PMID 30200406›Full record

SynthesisInternational journal of environmental research and public health2018

The Effectiveness and Cost-Effectiveness of Screening for and Vaccination Against Hepatitis B Virus among Migrants in the EU/EEA: A Systematic Review.

Daniel T Myran, Rachael Morton, Beverly-Ann Biggs, Irene Veldhuijzen, Francesco Castelli, Anh Tran, Lukas P Staub, Eric Agbata, Prinon Rahman, Manish Pareek and 2 more

Open access · goldAbstract readSystematic Review
PubMed Full text at PMC Publisher
In one paragraph

Synthesis in International journal of environmental research and public health, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 24 papers, 3 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
24citing papers in PubMed, 3 pooled it
2.4field-weighted citation impact, top 11% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

24 citing papers in PubMed, 3 syntheses or guidelines pooled it, 34 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Article
  5. Review
  6. Article
  7. Article
  8. Article
  9. Article
  10. Article
  11. Review
  12. Article
  13. Review
  14. Review
  15. Article
  16. Article
  17. Article
  18. Article
  19. Review
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors at 9 institutions in 7 countries.

Daniel T MyranUniversity of Ottawa School of Epidemiology and Public Health, Ottawa, ON K1G 5Z3, Canada. dmyra088@uottawa.ca.ORCID 0000-0002-8038-300X
Rachael MortonNHMRC Clinical Trials Centre, The University of Sydney, Sydney 2006, Australia. Rachael.morton@ctc.usyd.edu.au.ORCID 0000-0001-7834-0572
Beverly-Ann BiggsDepartment of Medicine at the Doherty Institute, University of Melbourne, and Victorian Infectious Diseases Service, Royal Melbourne Hospital, Melbourne 3000, Australia. babiggs@unimelb.edu.au.ORCID 0000-0002-2961-9793
Irene VeldhuijzenCentre for Infectious Disease Control, National Institute for Public Health and the Environment (RIVM), Bilthoven 3720, The Netherlands. irene.veldhuijzen@rivm.nl.
Francesco CastelliUniversity Department of Infectious and Tropical Diseases University of Brescia and ASST Spedali Civili, Brescia 25123, Italy. francesco.castelli@unibs.it.
Anh TranNHMRC Clinical Trials Centre, The University of Sydney, Sydney 2006, Australia. ahn.tran@ctc.usyd.edu.ar.
Lukas P StaubNHMRC Clinical Trials Centre, The University of Sydney, Sydney 2006, Australia. lukas.staub@ctc.usyd.edu.au.
Eric AgbataDepartment of Paediatrics, Obstetrics, Gynaecology and Preventive Medicine, Universität Autònoma de Barcelona, Barcelona 08193, Spain. ricagbata@yahoo.com.
Prinon RahmanC.T. Lamont Primary Health Care Research Centre, Bruyère Research Institute, Ottawa, ON K1R 7G5, Canada. prinon.rahman@dal.ca.
Manish PareekDepartment of Infection, Immunity and Inflammation, University of Leicester, Leicester LE1 7RH, UK. manish.pareek@leicester.ac.uk.
Teymur NooriEuropean Centre for Disease Prevention and Control, Stockholm 169 73, Sweden. Teymur.Noori@ecdc.europa.eu.ORCID 0000-0002-8935-749X
Kevin PottieBruyere Research Institute, School of Epidemiology and Public Health, University of Ottawa, Ottawa, ON K1R 7G5, Canada. kpottie@uottawa.ca.
The University of Sydney · AUUniversity of Ottawa · CABruyère · CAEuropean Centre for Disease Prevention and Control · SENational Institute for Public Health and the Environment · NLThe Royal Melbourne Hospital · AUUniversitat Autònoma de Barcelona · ESUniversity of Brescia · ITUniversity of Leicester · GB

Funding

Department of Health PDF-2015-08-102
6 · The paper itself

Abstract

Migrants from hepatitis B virus (HBV) endemic countries to the European Union/European Economic Area (EU/EEA) comprise 5.1% of the total EU/EEA population but account for 25% of total chronic Hepatitis B (CHB) infection. Migrants from high HBV prevalence regions are at the highest risk for CHB morbidity. These migrants are at risk of late detection of CHB complications; mortality and onwards transmission. The aim of this systematic review is to evaluate the effectiveness and cost-effectiveness of CHB screening and vaccination programs among migrants to the EU/EEA. We found no RCTs or direct evidence evaluating the effectiveness of CHB screening on morbidity and mortality of migrants. We therefore used a systematic evidence chain approach to identify studies relevant to screening and prevention programs; testing, treatment, and vaccination. We identified four systematic reviews and five additional studies and guidelines that reported on screening and vaccination effectiveness. Studies reported that vaccination programs were highly effective at reducing the prevalence of CHB in children (RR 0.07 95% CI 0.04 to 0.13) following vaccination. Two meta-analyses of therapy for chronic HBV infection found improvement in clinical outcomes and intermediate markers of disease. We identified nine studies examining the cost-effectiveness of screening for CHB: a strategy of screening and treating CHB compared to no screening. The median acceptance of HB screening was 87.4% (range 32.3⁻100%). Multiple studies highlighted barriers to and the absence of effective strategies to ensure linkage of treatment and care for migrants with CHB. In conclusion, screening of high-risk children and adults and vaccination of susceptible children, combined with treatment of CHB infection in migrants, are promising and cost-effective interventions, but linkage to treatment requires more attention.

Indexed as

Transients and MigrantsCost-Benefit AnalysisEuropean UnionHepatitis BHepatitis B virusHumansMass ScreeningVaccinationCHBHBVmigrantsrefugeesscreeningvaccination

Identifiers

PMID30200406
PMCPMC6164421
OpenAlexW2889317234

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.